NCT03141034View on ClinicalTrials.gov

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

April 14, 2023

Study Completion Date

April 14, 2023

Conditions
Gastric AdenocarcinomaGastro-esophageal Junction Adenocarcinoma
Interventions
DRUG

Irinotecan

-Irinotecan is commercially available and will be billed to insurance.

DRUG

Ramucirumab

-Ramucirumab will be provided free of charge by Eli Lilly and Company.

GENETIC

Blood for angiome profiling

-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment

GENETIC

Blood for cfDNA

-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment

Trial Locations (4)

33136

University of Miami - Sylvester Comprehensive Cancer Center, Miami

33612

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa

63110

Washington University School of Medicine, St Louis

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT03141034 - Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter